Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 9 | 2024 | 796 | 3.720 |
Why?
|
| Lipopeptides | 5 | 2021 | 61 | 2.920 |
Why?
|
| Clarithromycin | 4 | 2021 | 38 | 2.480 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2024 | 270 | 1.890 |
Why?
|
| Rifampin | 3 | 2020 | 58 | 1.750 |
Why?
|
| Klebsiella pneumoniae | 4 | 2023 | 20 | 1.710 |
Why?
|
| Acinetobacter baumannii | 3 | 2024 | 12 | 1.620 |
Why?
|
| Klebsiella Infections | 2 | 2023 | 13 | 1.560 |
Why?
|
| Carbapenems | 4 | 2024 | 17 | 1.390 |
Why?
|
| Cephalosporins | 3 | 2024 | 37 | 1.240 |
Why?
|
| Escherichia coli | 4 | 2023 | 181 | 1.080 |
Why?
|
| Gram-Negative Bacteria | 2 | 2017 | 34 | 1.060 |
Why?
|
| Acinetobacter Infections | 1 | 2024 | 8 | 0.870 |
Why?
|
| Galectin 1 | 1 | 2024 | 20 | 0.840 |
Why?
|
| Colistin | 1 | 2023 | 3 | 0.820 |
Why?
|
| Wound Infection | 1 | 2021 | 32 | 0.720 |
Why?
|
| Hydrogels | 1 | 2021 | 23 | 0.720 |
Why?
|
| Polymyxin B | 1 | 2021 | 4 | 0.720 |
Why?
|
| Vegetables | 1 | 2021 | 67 | 0.690 |
Why?
|
| Paenibacillus | 2 | 2017 | 6 | 0.670 |
Why?
|
| Polymyxins | 1 | 2020 | 3 | 0.660 |
Why?
|
| Escherichia coli Proteins | 1 | 2020 | 54 | 0.630 |
Why?
|
| Teichoic Acids | 1 | 2019 | 6 | 0.600 |
Why?
|
| beta-Lactamases | 3 | 2023 | 17 | 0.570 |
Why?
|
| Cell Membrane | 1 | 2019 | 231 | 0.560 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 204 | 0.540 |
Why?
|
| Gram-Positive Bacteria | 1 | 2017 | 15 | 0.530 |
Why?
|
| Peptides, Cyclic | 1 | 2017 | 41 | 0.520 |
Why?
|
| Biofilms | 1 | 2017 | 181 | 0.490 |
Why?
|
| Drug Synergism | 3 | 2020 | 148 | 0.430 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2021 | 76 | 0.330 |
Why?
|
| Mice | 3 | 2024 | 5877 | 0.270 |
Why?
|
| Animals | 4 | 2024 | 13332 | 0.270 |
Why?
|
| Humans | 10 | 2024 | 52114 | 0.260 |
Why?
|
| Sulbactam | 1 | 2024 | 5 | 0.220 |
Why?
|
| Azabicyclo Compounds | 1 | 2024 | 12 | 0.220 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2024 | 20 | 0.220 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2024 | 14 | 0.210 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 57 | 0.210 |
Why?
|
| DNA Transposable Elements | 1 | 2024 | 107 | 0.210 |
Why?
|
| Proton Therapy | 1 | 2023 | 12 | 0.210 |
Why?
|
| Receptors, Cell Surface | 1 | 2024 | 110 | 0.210 |
Why?
|
| Porins | 1 | 2023 | 4 | 0.200 |
Why?
|
| Intestine, Small | 1 | 2024 | 115 | 0.200 |
Why?
|
| Siderophores | 1 | 2022 | 5 | 0.190 |
Why?
|
| Interleukin-6 | 1 | 2024 | 274 | 0.190 |
Why?
|
| Food Supply | 1 | 2023 | 92 | 0.190 |
Why?
|
| Transglutaminases | 1 | 2021 | 14 | 0.180 |
Why?
|
| Biocatalysis | 1 | 2021 | 15 | 0.180 |
Why?
|
| Gelatin | 1 | 2021 | 22 | 0.180 |
Why?
|
| Enterobacter | 1 | 2021 | 6 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 285 | 0.160 |
Why?
|
| DNA Adducts | 1 | 2020 | 79 | 0.160 |
Why?
|
| Escherichia coli Infections | 1 | 2020 | 28 | 0.160 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 399 | 0.150 |
Why?
|
| beta-Lactam Resistance | 1 | 2018 | 2 | 0.150 |
Why?
|
| Skin | 1 | 2021 | 418 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 76 | 0.140 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 337 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2018 | 134 | 0.140 |
Why?
|
| Quality of Life | 1 | 2024 | 878 | 0.140 |
Why?
|
| Hemolysis | 1 | 2017 | 28 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2018 | 231 | 0.140 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 45 | 0.130 |
Why?
|
| Antibiosis | 1 | 2017 | 2 | 0.130 |
Why?
|
| Cyclization | 1 | 2017 | 5 | 0.130 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2017 | 30 | 0.130 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 404 | 0.130 |
Why?
|
| Cell Survival | 1 | 2018 | 596 | 0.130 |
Why?
|
| Mutation | 1 | 2022 | 1318 | 0.130 |
Why?
|
| Peptides | 1 | 2017 | 234 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 335 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 312 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2014 | 128 | 0.100 |
Why?
|
| Male | 2 | 2024 | 26652 | 0.100 |
Why?
|
| Female | 2 | 2021 | 28055 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2023 | 1148 | 0.050 |
Why?
|
| Neoplasms | 1 | 2014 | 1288 | 0.050 |
Why?
|
| Acrylamides | 1 | 2023 | 8 | 0.050 |
Why?
|
| Gels | 1 | 2023 | 22 | 0.050 |
Why?
|
| Polymers | 1 | 2023 | 50 | 0.050 |
Why?
|
| Protons | 1 | 2023 | 71 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 399 | 0.050 |
Why?
|
| Surface Properties | 1 | 2020 | 62 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 2020 | 101 | 0.040 |
Why?
|
| Particle Size | 1 | 2020 | 78 | 0.040 |
Why?
|
| Plasmids | 1 | 2020 | 164 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 315 | 0.040 |
Why?
|
| DNA | 1 | 2020 | 543 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2014 | 25 | 0.030 |
Why?
|
| Radiometry | 1 | 2014 | 127 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 260 | 0.020 |
Why?
|